STC Link

STC Link is a South Korean biotechnology company and a core entity of the STC Group, specializing in regenerative medicine and longevity science. The company is primarily focused on its proprietary STC-EPN technology, which involves producing pluripotent stem cells using natural compounds to avoid the ethical and safety concerns associated with embryonic stem cells. Its research heavily emphasizes the p62 (Sequestosome 1) gene, which the company identifies as a critical regulator of cellular autophagy and repair mechanisms. STC Link maintains a broad pipeline targeting neurodegenerative diseases, stroke, and chronic organ damage, while also exploring commercial applications in longevity and medical aesthetics. Through its affiliated research institute (STRI), the company holds an extensive international patent portfolio for mass-producing high-potency stem cells and gene-targeted anti-aging therapies.